From viral capsids to bacterial toxins, a core set of high-purity recombinant antigens forms the backbone of multiplex immunoassay panels for high-throughput infectious disease diagnostics. The primary targets span Hepatitis B virus surface, core, and envelope antigens; Hepatitis C virus core and nonstructural proteins NS3, NS4, and NS5; HIV-1 p24 capsid, gp120, and gp41 envelope glycoproteins; influenza A and B hemagglutinin and nucleoprotein; HPV L1 capsid protein; Chlamydia trachomatis major outer membrane protein and LPS; Bordetella pertussis toxin and filamentous hemagglutinin; Helicobacter pylori CagA and VacA; Mycobacterium tuberculosis ESAT-6 and CFP-10; and cholera toxin B subunit—plus parasitic stage-specific markers like Toxoplasma gondii GRA2 and ROP1.
Multiplex panel success depends not only on which antigens you put in, but on how those antigens are produced and integrated. Recombinant, natively folded targets with well-defined epitopes minimize cross‑reactivity, maintain wide dynamic ranges, and enable reliable high‑throughput analysis—turning a simple list of pathogens into a robust, quantitative surveillance tool.
Essential Viral Antigens for Serological Surveillance
Building a multiplex panel starts with the structural and non‑structural proteins that the immune system recognizes most reliably after infection or vaccination. These antigens must be produced as soluble, stable proteins that retain conformational epitopes.
Hepatitis B Virus: The Three‑Part Serological Profile
Three distinct antigens map the stage of HBV infection and immune status.
- Hepatitis B surface antigen (HBsAg) is the hallmark of active infection and the primary target for screening.
- Hepatitis B core antigen (HBcAg) elicits strong, persistent IgM and IgG responses; antibodies appear early and remain for life, making it an excellent marker for past or ongoing infection.
- Hepatitis B e antigen (HBeAg) indicates high levels of viral replication and infectivity. Including all three in a multiplex panel allows simultaneous assessment of infection phase without reflex testing.
Hepatitis C Virus: Non‑Structural Proteins as Diagnostic Anchors
Because HCV rarely yields robust anti‑structural responses in early infection, multiplex panels lean heavily on non‑structural targets.
- The core protein provides early seroconversion signals.
- NS3, NS4, and NS5 recombinant proteins are used in combination to improve sensitivity across genotypes and to differentiate resolved from chronic infection. High‑purity recombinant fusions of these non‑structural proteins enable a single‑well “combo” signal while still preserving individual reactivity data.
HIV‑1: Combining Capsid and Envelope for Early Detection
A multiplex panel for HIV‑1 needs both early‑appearing and broadly reactive markers.
- p24 capsid antigen is the first viral protein detectable in blood, enabling fourth‑generation assay strategies that combine antigen and antibody detection.
- gp41 and gp120 envelope glycoproteins serve as confirmation targets. Recombinant gp41, in particular, provides high specificity for anti‑HIV antibodies and is often used to resolve borderline results.
Influenza A/B and HPV: Typing and Screening in One Panel
For respiratory and cancer‑prevention screening, broad‑coverage antigens give high‑throughput platforms their population‑scale value.
- Influenza A and B nucleoprotein (NP) is conserved and type‑specific; including recombinant NP from circulating strains creates a universal influenza immunity fingerprint.
- Hemagglutinin (HA) from H1, H3, and B lineages refines strain‑level information and can monitor vaccine responses.
- HPV L1 capsid protein—assembled into virus‑like particles—detects type‑specific antibodies and underpins serosurveillance for vaccination coverage.
Bacterial and Parasitic Targets for Comprehensive Pathogen Screening
Bacterial serology in multiplex format benefits from defined virulence factors and toxins that are highly immunogenic and absent from normal flora.
Respiratory and Genitourinary Pathogens
- Chlamydia trachomatis: The major outer membrane protein (MOMP) and lipopolysaccharide (LPS) provide genus‑ and species‑level specificity. Recombinant MOMP solves the batch‑inconsistency problems of native antigen preparations.
- Bordetella pertussis: Key antigens include pertussis toxin (PT) for toxin‑specific IgG, filamentous hemagglutinin (FHA), and pertactin. Including all three helps differentiate vaccine‑induced immunity from recent infection.
Gastrointestinal and Systemic Bacterial Targets
- Helicobacter pylori: CagA (cytotoxin‑associated gene A) and VacA (vacuolating cytotoxin) are virulence‑linked antigens that distinguish pathogenic strains from commensals. Combined with urease subunits, they offer a complete serological picture.
- Mycobacterium tuberculosis: ESAT‑6 and CFP‑10 are the critical RD1‑region antigens absent from BCG, enabling specific detection of TB infection in multiplex panels. Adding the Ag85 complex further boosts sensitivity.
- Cholera Toxin B subunit: The non‑toxic binding moiety of cholera toxin elicits strong anti‑toxin antibodies and serves as a stable, safe recombinant target for monitoring vaccine response or exposure.
Parasitic Infections: Stage‑Specific Antigens
- Toxoplasma gondii GRA2 and ROP1 recombinant proteins allow precise differentiation of acute and chronic IgG profiles. Because these dense granule and rhoptry antigens appear at distinct infection phases, multiplex panels that include both markers significantly reduce the need for avidity testing.
Building a High‑Throughput Multiplex Panel: The Recombinant Advantage
The transition from a list of targets to a working panel hinges on material quality and assay architecture. Recombinant antigens are not a luxury—they are a technical necessity for high‑throughput settings.
Consistent Epitope Presentation Eliminates False Readings
Recombinant proteins overcome the lot‑to‑lot variability of native pathogen lysates. High‑purity, natively folded antigens—whether expressed in mammalian, insect, or E. coli systems with optimized refolding—ensure that conformational epitopes are intact. This directly prevents false‑negative results that arise when critical binding sites are denatured.
Managing Cross‑Reactivity and Dynamic Range
The primary challenge in multiplex immunoassays is antibody cross‑reactivity. Even highly specific monoclonal antibody pairs can produce off‑target signals when dozens of analytes are measured in one well.
- Paired antibody screening must be performed in multiplex‑realistic buffers, not just single‑plex conditions.
- Recombinant antigens can be engineered to remove cross‑reactive domains (e.g., eliminating Fc‑binding regions or common alpha‑helical motifs) without compromising epitope exposure.
- Balanced reaction buffers with carefully selected blocking agents and ionic strengths minimize non‑specific binding across the entire panel.
- Calibrated signal detection controls for each analyte ensure that high‑abundance targets (like total influenza NP antibodies) do not bleed into low‑signal channels (like early‑stage HIV p24).
Microfluidic Integration for Speed and Low Sample Volume
Supplementary technologies such as acoustic micro‑stirring or electric field acceleration drastically shorten incubation times. When combined with high‑density surface functionalization, these non‑invasive mixing techniques bring multiplex reaction kinetics in line with truly high‑throughput workflows—providing quantitative results for 10–50 targets in under 15 minutes.
Understanding the Trade‑Offs
No multiplex panel is without compromise. Knowing the pitfalls upfront is essential to building a platform that regulatory reviewers and clinicians can trust.
Cross‑Reactivity Between Related Pathogens
A flavivirus‑naïve panel will struggle if you combine dengue, Zika, and yellow fever antigens. The structural similarity of envelope proteins can cause mutual interference. Adjusting for cross‑reactivity often means careful antigen design (e.g., using domain‑specific fragments) or accepting slightly reduced sensitivity in exchange for specificity.
The Risk of Antigen Competition and Hook Effects
When antigens vary widely in the expected antibody concentration range, high‑titer responses (e.g., anti‑influenza NP post‑vaccination) can consume signal detection reagents or saturate capture surfaces, masking the signal from a low‑titer marker like early HIV p24. Multiplex panel design must include dynamic range checks—assaying samples at multiple dilutions or using on‑bead signal normalization—to prevent false negatives.
Lot‑to‑Lot Consistency and Regulatory Hurdles
Recombinant manufacturing is the only scalable way to meet the consistency requirements of IVD regulatory bodies. Yet even recombinant proteins can aggregate or degrade over time. Accelerated stability studies and forced‑degradation analyses are non‑negotiable when your panel moves from R&D to verification.
Making the Right Choice for Your Diagnostic Goal
Your target selection strategy should flow directly from the clinical question the panel is meant to answer. Use the recommendations below to align antigen choice with assay purpose.
- If your primary focus is broad serosurveillance: Prioritize conserved, immunodominant antigens like influenza NP, HBV core, and HIV‑1 gp41. These give population‑level detection with minimal interference and allow a single dilution to capture the breadth of immunity.
- If your primary focus is differentiating infection stages: Pair early‑ and late‑appearing markers—for example, HIV p24 plus gp41, or Toxoplasma GRA2 with ROP1. Validate the linear range of each assay independently under multiplex conditions to avoid the hook effect masking early signal.
- If your primary focus is distinguishing vaccine‑induced immunity from natural infection: Include non‑vaccine targets such as hepatitis B core antigen (HBcAg) or M. tuberculosis ESAT‑6/CFP‑10. Using highly purified recombinant forms of these antigens eliminates background from vaccine cross‑reactive materials.
By anchoring your high‑throughput panel in well‑characterized, recombinant antigens and meticulously controlling cross‑reactivity and dynamic range, you transform a collection of pathogen markers into a definitive, actionable diagnostic tool.
Summary Table:
| Pathogen Category | Target Pathogens | Key Antigens / Biomarkers | Diagnostic Utility &
| Application |
|---|
| Viral Targets |
| Bacterial Targets |
| Parasitic Targets |
Accelerate your diagnostic assay development with high-purity recombinant targets. CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials, custom technical services, and expert consulting—supporting every stage of your project from concept to clinic. Contact CamelBio today to resolve panel cross-reactivity and secure stable raw materials for your multiplex assays.